+1 Recommend
1 collections
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Mitomycin C Influence on Inhibition of Cellular Proliferation and Subsequent Synthesis of Type I Collagen and Laminin in Primary and Recurrent Pterygia


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The purpose was to investigate the biological effects of mitomycin C (MMC) on the inhibition of cellular proliferation and the subsequent synthesis of extracellular matrix like type I collagen (PIP) and laminin on primary and recurrent pterygia. The <sup>3</sup>H-thymidine assay for cellular proliferation was consistent with the MMC dose and time response of both pterygia. The cellular inhibitory effect of MMC was greater on recurrent pterygial cells than primary ones. The inhibition of laminin by MMC followed the dose and time-response curves, with a stronger effect found in recurrent pterygial cells, but no significant difference between the two types concerning type I collagen synthesis. The inhibition of fibroblast proliferation and subsequent synthesis of laminin by MMC was more marked in recurrent pterygium than the primary one.

          Related collections

          Author and article information

          Ophthalmic Res
          Ophthalmic Research
          S. Karger AG
          June 2001
          04 May 2001
          : 33
          : 3
          : 140-146
          Department of Ophthalmology, Research Institute of Medical Science, College of Medicine, Pusan National University, Pusan City, Korea
          55660 Ophthalmic Res 2001;33:140–146
          © 2001 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 4, Tables: 3, References: 22, Pages: 7
          Original Paper

          Vision sciences,Ophthalmology & Optometry,Pathology
          Type I collagen (PIP),Mitomycin C,Laminin,Primary and recurrent pterygia


          Comment on this article